These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1588 related items for PubMed ID: 345817

  • 41. Adrenocortical function of patients using oral contraceptives.
    Kauppila A, Järvinen PA, Ylöstalo P, Reinilä M.
    Acta Obstet Gynecol Scand; 1974; 53(2):155-9. PubMed ID: 4362662
    [Abstract] [Full Text] [Related]

  • 42. The effect of oral contraceptives on the gonadotropin response to LHRH.
    Rubinstein L, Moguilevsky J, Leiderman S.
    Obstet Gynecol; 1978 Nov; 52(5):571-4. PubMed ID: 364356
    [Abstract] [Full Text] [Related]

  • 43. The effect of norethisterone (500 mcg) and ethinyl estradiol (35 mcg) capsules on the pituitary-ovarian axis.
    Nuttall ID, Elstein M, Fahmy DR.
    Contraception; 1982 May; 25(5):463-9. PubMed ID: 6809424
    [Abstract] [Full Text] [Related]

  • 44. Oral contraceptive agents.
    Shearman RP.
    Med J Aust; 1986 Feb 17; 144(4):201-5. PubMed ID: 3945219
    [Abstract] [Full Text] [Related]

  • 45. The effects of estrogen and progesterone on the functional capacity of the gonadotrophs.
    Lasley BL, Wang CF, Yen SS.
    J Clin Endocrinol Metab; 1975 Nov 17; 41(5):820-6. PubMed ID: 1102551
    [Abstract] [Full Text] [Related]

  • 46. Effects of RU16117, an orally active weak oestrogenic compound, in postmenopausal women.
    Faure N, Labrie F, Olivier G, Tremblay M, Cloutier D, Lemay A, Ferland L, Azadian-Boulanger G, Bouton MM, Husson JM, Raynaud JP.
    Maturitas; 1980 Jul 17; 2(2):155-68. PubMed ID: 6782429
    [Abstract] [Full Text] [Related]

  • 47. Oral contraceptives, lipoproteins, and atherosclerosis.
    Adams MR, Clarkson TB, Shively CA, Parks JS, Kaplan JR.
    Am J Obstet Gynecol; 1990 Oct 17; 163(4 Pt 2):1388-93. PubMed ID: 2220963
    [Abstract] [Full Text] [Related]

  • 48. Biphasic change in pituitary capacity induced by estrogen in hypogonadal women.
    Lachelin GC, Yen SS.
    J Clin Endocrinol Metab; 1978 Mar 17; 46(3):369-73. PubMed ID: 109457
    [Abstract] [Full Text] [Related]

  • 49. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
    van Heusden AM, Fauser BC.
    Contraception; 1999 Apr 17; 59(4):237-43. PubMed ID: 10457868
    [Abstract] [Full Text] [Related]

  • 50. The fallacy of the postpill amenorrhea syndrome.
    Archer DF, Thomas RL.
    Clin Obstet Gynecol; 1981 Sep 17; 24(3):943-50. PubMed ID: 6793275
    [Abstract] [Full Text] [Related]

  • 51. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P, Walden C, Knopp R, Hoover J, Wallace R, Heiss G, Rifkind B.
    N Engl J Med; 1983 Apr 14; 308(15):862-7. PubMed ID: 6572785
    [Abstract] [Full Text] [Related]

  • 52. Studies on low dose oral contraceptives: plasma hormone changes in relation to deliberate pill ('Microgynon 30') omission.
    Morris SE, Groom GV, Cameron ED, Buckingham MS, Everitt JM, Elstein M.
    Contraception; 1979 Jul 14; 20(1):61-9. PubMed ID: 477318
    [Abstract] [Full Text] [Related]

  • 53. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A, Brache V, Tejada AS, Cochon L, Alvarez-Sanchez F.
    Fertil Steril; 1991 Jul 14; 56(1):27-31. PubMed ID: 1906017
    [Abstract] [Full Text] [Related]

  • 54. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol.
    Goebelsmann U, Mashchak CA, Mishell DR.
    Am J Obstet Gynecol; 1985 Apr 01; 151(7):868-77. PubMed ID: 3920910
    [Abstract] [Full Text] [Related]

  • 55. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF, Crook D, Devenport M, Wynn V.
    Contraception; 1995 Sep 01; 52(3):143-9. PubMed ID: 7587185
    [Abstract] [Full Text] [Related]

  • 56. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K, Rolland R, Brosens I, Moorrees M, Deprest J, Tuominen J, Lähteenmäki P.
    Am J Obstet Gynecol; 1998 Jul 01; 179(1):41-6. PubMed ID: 9704763
    [Abstract] [Full Text] [Related]

  • 57. Control of fertility with oral medication.
    Diddle AW, Watts GF, Gardner WH, Williamson PJ.
    West J Surg Obstet Gynecol; 1964 Jul 01; 72():222-9. PubMed ID: 12305556
    [Abstract] [Full Text] [Related]

  • 58. [Sensitivity of the pituitary gland to LH-FSH releasing hormone in women after discontinuation of ovidon, an estrogen-progesterone contraceptive agent].
    Nikanorova SA, Kononova ES, Chembartseva AN.
    Akush Ginekol (Mosk); 1982 Oct 01; (10):40-1. PubMed ID: 6817648
    [Abstract] [Full Text] [Related]

  • 59. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R, Messinis LE, Fowler P, Groome NP, Knight PG, Templeton AA.
    Hum Reprod; 1996 Dec 01; 11(12):2585-90. PubMed ID: 9021355
    [Abstract] [Full Text] [Related]

  • 60. Effects of combined oral contraceptive steroids on pituitary-ovarian function during the menstrual cycle of lactating women.
    Ryu K, Yu HK, Kwak HM, Hong SS.
    Contraception; 1983 Mar 01; 27(3):299-310. PubMed ID: 6406140
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 80.